Latest News - Dry Eye

Thursday, November 09, 2017 | Dry Eye, Milestones, Johnson & Johnson Vision Care, TearScience

Johnson & Johnson Vision Announces TearScience LipiScan and LipiFlow Now Available in More Than 800 Eye Care Practices

TearScience, now a part of Johnson & Johnson Vision, announced at the American Academy of Ophthalmology (AAO) 2017 Meeting that its LipiScan and LipiFlow technologies are now available in more tha…

Read the full story

Wednesday, October 25, 2017 | Dry Eye, Medical Studies

Study: Patients Using Rohto Dry Aid Report All-Day Relief of Ocular Signs and Symptoms of Dry Eye Disease

Rohto Dry Aid, a new over-the-counter (OTC) lubricant eye drop was found to show superior relief of discomfort associated with visual tasking activities, and may provide a longer duration of symptomat…

Read the full story

Friday, October 20, 2017 | Dry Eye

Aurinia to Expand Renal Franchise with Novel Indications and Launches Development Program for Treatment of Dry Eye Syndrome

Aurinia Pharmaceuticals announced plans to expand its voclosoprin renal franchise to include focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD). Additionally, Aurinia announced…

Read the full story

Thursday, October 19, 2017 | Dry Eye, Product Releases, Imprimis Pharmaceuticals

Imprimis Pharmaceuticals to Offer Compounded Cyclosporine

Imprimis Pharmaceuticals announced it is making compounded cyclosporine-based formulations for dry eye disease. The formulations, which will be packaged in a preservative-free bottle, are patent-pendi…

Read the full story

Monday, October 02, 2017 | Awards, Dry Eye, Novaliq

German Ophthalmological Society (DOG) Honors Uta Gehlsen, PhD, for Research On the Use of Semifluorinated Alkanes in Dry Eye Treatment

The German Ophthalmological Society (DOG) presented Uta Gehlsen, PhD, Ocular Surface Group, Department of Ophthalmology, University of Cologne, with the “Dry Eye and Blepharitis/MGD” Award…

Read the full story

Monday, October 02, 2017 | Corporate Lawsuits, Dry Eye, Allergan, Shire

Shire Alleges Allergan Blocked Drug From Medicare Contracts

Shire filed an antitrust suit against Allergan alleging Allergan’s contracts with Medicare Part D drug plans for its Restasis eye drops effectively blocked access to Shire’s rival drug, ac…

Read the full story

Tuesday, August 15, 2017 | Dry Eye, Shire

Shire Applies for European Approval for Dry Eye Drug Lifitegrast

Shire announced that it has submitted a Marketing Authorization Application (MAA) in the UK for lifitegrast for the treatment of dry eye disease. The application, submitted on August 7, 2017, has been…

Read the full story

Friday, July 21, 2017 | CE Mark Approval, Dry Eye, TearLab Corp.

TearLab Announces European Regulatory Clearance for Next-Generation TearLab Discovery System

TearLab announced that the commercial version of its next-generation in-vitro diagnostics testing platform, the TearLab Discovery System, has received CE Marking, providing clearance in the European U…

Read the full story

Friday, July 21, 2017 | Dry Eye, Medical Studies

TFOS DEWS II Report Published; Dry Eye Disease Redefined

The long-awaited Tear Film & Ocular Surface Society (TFOS) Dry Eye Workshop II (DEWS II) report was published on July 21, 2017, updating the definition of dry eye disease (DED) and potentially imp…

Read the full story

Wednesday, May 31, 2017 | Clinical Trials, Dry Eye

Lamellar Biomedical Recruits First Patients into Clinical Study Assessing Lamelleye for Treatment of Dry Eye Disease

Lamellar Biomedical announced the recruitment of the first patients in a clinical study assessing Lamelleye for the treatment of moderate to severe dry eye disease (DED). Lamelleye is designed to prov…

Read the full story

Monday, May 01, 2017 | Dry Eye, Partnerships, Parion Sciences, Shire

Shire and Parion Sciences Enter into a Collaborative License Agreement to Advance P-321 for Ophthalmic Indications

Shire and Parion Sciences announced they have entered into an agreement granting Shire exclusive worldwide rights to develop and commercialize P-321. Shire will lead development of P-321, an investi…

Read the full story

Thursday, April 06, 2017 | Acquisitions/Mergers, Dry Eye, Imprimis Pharmaceuticals

Imprimis Pharmaceuticals Acquires Exclusive License to Patented Ophthalmic Formulation for Dry Eye Disease

Imprimis Pharmaceuticals announced that it has entered into an licensing agreement for the exclusive worldwide rights to Klarity, a patented ophthalmic topical solution and gel technology for patients…

Read the full story

Monday, March 20, 2017 | Dry Eye, Pharmaceutical, Novaliq

Novaliq Announces Licensing Agreement With AFT Pharmaceuticals for Distribution of NovaTears

Novaliq announced a strategic licensing agreement with AFT Pharmaceuticals for the commercialization of Novaliq's lead product NovaTears in Australia and New Zealand. NovaTears is Novaliq&rsquo…

Read the full story

Friday, February 17, 2017 | Dry Eye, Earnings & Financials, Shire

Shire Provides Update on Early Xiidra Sales

As part of its fourth quarter and full-year earnings release on Thursday, Shire provided information about the early sales of its dry eye disease drug Xiidra (lifitegrast), which was launched in Augus…

Read the full story

Tuesday, January 17, 2017 | Dry Eye, Medical Studies

Faster Diagnosis Could Improve Quality of Life for People With Dry Eye Disease

Dry eye disease can be difficult to diagnose, and delays in diagnosis may lead to more severe symptoms and a greater impact on patients' daily lives, according to a European study. People with a d…

Read the full story
Load More